Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akerley

Showing results (171-180 of 227) with videos related to

Pageof 23
Sort By:
Plos One|January 16, 2020
Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencingGeorge W Cook, Michael G Benton, Wallace Akerley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II studyJonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingMelanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
Cancer|February 28, 2026
Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunitiesSonam Puri, Andrew Elliott, Abdul Rafeh Naqash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Small cell lung cancerGregory P Kalemkerian, Wallace Akerley, Robert J Downey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2022
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory GroupPeter D Stetson, Nadine J McCleary, Travis Osterman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2008
NCCN Task Force Report: mTOR inhibition in solid tumorsRobert A Figlin, Elizabeth Brown, Andrew J Armstrong, et al.
Oncotarget|December 6, 2022
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. studyConnor Willis, Hillevi Bauer, Trang H Au, et al.
Pageof 23

Showing results (171-180 of 227) with videos related to

Sort By:
Pageof 23
Plos One|January 16, 2020
Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencingGeorge W Cook, Michael G Benton, Wallace Akerley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II studyJonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingMelanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
Cancer|February 28, 2026
Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunitiesSonam Puri, Andrew Elliott, Abdul Rafeh Naqash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Small cell lung cancerGregory P Kalemkerian, Wallace Akerley, Robert J Downey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2022
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory GroupPeter D Stetson, Nadine J McCleary, Travis Osterman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2008
NCCN Task Force Report: mTOR inhibition in solid tumorsRobert A Figlin, Elizabeth Brown, Andrew J Armstrong, et al.
Oncotarget|December 6, 2022
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. studyConnor Willis, Hillevi Bauer, Trang H Au, et al.
Pageof 23